Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2010.

Cash, cash equivalents, and short-term investments at September 30, 2010 were $303.3 million as compared to $396.2 million at December 31, 2009.

Revenue for the third quarter of 2010 increased to $37.9 million as compared to $10.2 million in the third quarter of 2009.  The increase in revenue year over year is largely the result of the amortization of the $125 million milestone payment received from AstraZeneca in September 2009 under the partnership agreement for NKTR-118.  

Total operating costs and expenses in the third quarter of 2010 were $44.2 million compared to $39.1 million in the third quarter 2009. The increase in total operating costs and expenses was primarily due to an increase in research and development expenses.

Research and development expenses were $27.7 million and increased by 20% in the third quarter of 2010 as compared to $23.0 million for the same quarter in 2009.  General and administrative expense increased slightly to $10.2 million in the third quarter 2010 from $9.9 million in the third quarter of 2009.

“Nektar’s continued productivity in research and development has resulted in a deep pipeline of programs that range from those in preclinical research to those preparing for Phase 3,” said Howard W. Robin, President and Chief Executive Officer of Nektar.  “With our Phase 2 data this year from our exciting oncology candidate, NKTR-102, and the preclinical data from our new opioid candidate, NKTR-181, we continue to demonstrate the value of Nektar’s proprietary polymer conjugate technology.”

Net loss for the third quarter ended September 30, 2010 decreased to $8.7 million or $0.09 per share
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 The March 3, 2015, order from ... must change their products, labels to clarify the drugs, intended ... and stroke is necessary to protect the public from injury ... partner at Simmons Hanly Conroy . The ... that the products – currently taken by millions of U.S. ...
(Date:3/4/2015)... CITY, Kan. , March 4, 2015   ... a pet therapeutics company focused on the licensing, development ... today announced that it will present at the ... 10-12, 2015, at the Loews Miami Beach Hotel in ... Steven St. Peter , M.D., President and Chief ...
(Date:3/4/2015)... N.J. , March 4, 2015  Bayer ... Drug Administration (FDA) has accepted the company,s Biologics ... Factor VIII compound.  Bayer is seeking FDA approval ... for the treatment of hemophilia A in children ... to continually bringing new therapies to hemophilia A ...
Breaking Medicine Technology:Simmons Hanly Conroy, LLC: FDA Orders Label Warnings on Testosterone Drugs Concerning Normal Aging Use and Heart Attack-Stroke Risks 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3
... , May 10 /PRNewswire-Asia/ -- On April ... cases with Beijing Un-Assegai Technical &,Trade Co. Ltd. (hereinafter referred ... China , as claimant and U.S. Abbott,Laboratories (Abbott U.S.; ... by the,China International Economic and Trade Arbitration Commission (CIETAC), which,has ...
... , Fla., May 10 Dr. Richard ... with newly diagnosed type 1 diabetes for Protege Encore, a ... of two Phase III studies testing the safety and efficacy ... as Protege, has completed enrollment of more than 530 subjects ...
Cached Medicine Technology:Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes 2
(Date:3/5/2015)... COVINGTON, LOUISIANA (PRWEB) March 05, 2015 ... announce its continued support of the annual American Heart ... This year, Bret Kolman, Lakeview Regional Chief Executive Officer, ... take place on Saturday, March 21, 2015 at Fontainebleau ... event sponsorship, Lakeview Regional has 20 individual teams participating ...
(Date:3/5/2015)... New fiber fix heat wrap, a fiber glass adhesive launched ... kind product, manufactured to withstand the highest of temperatures. This ... in the market by customers who look to mold together ... cannot be done with the usual adhesives. , A spokesperson ... our new product Fiber Fix Heat Warp and already see ...
(Date:3/5/2015)... The cornerstone of the Vacuworx design ... smarter commercial lifting system and with the introduction of ... in more green construction projects . , Vacuworx ... System for lifting concrete road slabs and the Hydraulic ... projects. , The Octapad System was designed with ...
(Date:3/5/2015)... March 05, 2015 March is ... information campaign sponsored by the Academy of Nutrition ... a Healthy Lifestyle," which promotes the consumption of ... for achieving and maintaining a healthy weight, reducing ... , Whether a person is new to ...
(Date:3/5/2015)... Medical professionals suggest the physician shortage is no ... is worsening. The demand for doctors far exceeds the ... of the physician shortage, health care organizations and medical ... physicians and advanced practitioners throughout the U.S. through a ... Physician openings take an average of 204 days to ...
Breaking Medicine News(10 mins):Health News:Get Your Heart Set on Walking a Better "Path" - Lakeview Regional Medical Center Sponsors Northshore Heart Walk 2Health News:Get Your Heart Set on Walking a Better "Path" - Lakeview Regional Medical Center Sponsors Northshore Heart Walk 3Health News:TheHardwareCity.com Launches New Fiber Fix Heat Wrap For High Temperature Applications 2Health News:New Vacuworx Concrete Lifting Systems Aid Safer, Greener Environment As Contractors Seek LEED Incentives 2Health News:New Vacuworx Concrete Lifting Systems Aid Safer, Greener Environment As Contractors Seek LEED Incentives 3Health News:National Nutrition Month® Tips for Athletes from the Austin Sports Medicine Team at Medicine in Motion 2Health News:National Nutrition Month® Tips for Athletes from the Austin Sports Medicine Team at Medicine in Motion 3Health News:Physician Shortage Crisis Worsening 2
... painful rashes. Prescription medications including steroid creams that ... ,When over five million Americans suffer from that ... frenzied response, especially when backed by some kind of ... even though experts are skeptical. ,"We can ...
... of anthropologists have embarked on a project to save Tibetan ... professor Gerald Roche, the volunteer-run Tibetan Endangered Music Project (TEMP) ... and return them back to the community. ,"The ... them to our communities. We want to record as many ...
... countries holding an international summit on bird flu in Aviemore ... birds are not an answer to the outbreaks of ... the Avian Flu Task Force under the UN international convention ... wild birds have been infected in some cases, the scientists ...
... to help people quit smoking? Get a national TV network ... of a new study that found calls to a national ... anchor Peter Jennings death from lung cancer. ,Its ... also have to advertise it, said Erik Augustson, a behavioral ...
... be negative, write Professor Desmond O'Neill and colleagues. Yet ... prudent driving behaviours. Furthermore, stopping driving can limit ... independent risk factor for entry into a nursing home. ... therefore try to balance mobility and safety in the ...
... Alteon Inc. announced today that it has dosed ... trial (Study 201) of ALT-2074, its lead glutathione peroxidase ... haptoglobin that renders them at high risk for cardiovascular ... designed to evaluate ALT-2074's ability to lower inflammatory cardiovascular ...
Cached Medicine News:Health News:Experts Critical of a New OTC Product to Treat Psoriasis 2Health News:Experts Critical of a New OTC Product to Treat Psoriasis 3Health News:Digital Music Project Aims to Save Tibetan Folk Songs from Extinction 2Health News:National TV Promotion Triples Calls to Smoking Cessation Hotline 2Health News:Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2 2
... enables highly sensitive time-resolved fluorescence detection ... fluorophores. These compounds are excited with ... fluorescence lifetimes (several hundred microseconds), large ... profiles at 620 nm. Therefore with ...
... most advanced multi-functional microplate detection system, ... performance without compromising flexibility. ,The ... on the Ultra instrument platform. New ... adds to the flexibility of the ...
... OPTIMA is a fully automated microplate ... different measurement principles:, , Fluorescence Polarization ... Fluorescence , High-Performance Luminescence (flash ... ,It is designed for the ...
... FLUOstar is a flexible multifunction plate reader ... one instrument: fluorescence intensity, time-resolved fluorescence, high-perfomance ... be equipped with injectors that deliver reagent ... fast kinetic cell assays can be performed ...
Medicine Products: